Apogee Therapeutics Business Summary

Apogee Therapeutics, Inc. (APGE) is a clinical-stage biotechnology company specializing in the development of differentiated biologics for immunological and inflammatory (I&I) disorders, including atopic dermatitis, chronic obstructive pulmonary disease (COPD), and asthma. The company operates as a pre-revenue entity, deriving its valuation from the clinical progression of its proprietary pipeline, which is supported by a robust cash position of approximately $913 million as of early 2026. Its primary business segments are defined by its lead monoclonal antibody programs: APG777 (an anti-IL-13 mAb) and APG808 (an anti-IL-4Rα mAb), both of which utilize advanced half-life extension technology to enable significantly less frequent dosing than current therapies. Apogee competes directly with Sanofi/Regeneron (Dupixent), Eli Lilly (Ebglysz), Amgen (Tezspire), and BridgeBio Pharma. The company positions itself as a "best-in-class" challenger in the $50 billion+ I&I market, aiming to disrupt established biologics by offering superior patient convenience through quarterly or semi-annual dosing regimens. Founded in 2022 by Nimish Shah, a Partner at Venrock, Apogee is led by Chief Executive Officer Michael Henderson, MD, who previously served as Chief Asset Management Officer at BridgeBio Pharma. The senior leadership team includes Chief Financial Officer Jane Pritchett Henderson, formerly of Adicet Bio, Chief Medical Officer Carl Dambkowski, MD, and Chief Development Officer Rebecca Dabora, PhD, who oversees the technical and clinical advancement of the pipeline. The company’s strategic direction is guided by a high-pedigree board of directors chaired by Mark C. McKenna, the former CEO of Prometheus Biosciences. Apogee is backed by a syndicate of prominent institutional investors, including Venrock, Fairmount Funds, RTW Investments, and Deep Track Capital, with additional significant positions held by Perceptive Advisors and T. Rowe Price, reflecting deep market conviction in the company’s engineering-led approach to immunology.